PFE · News · 20260922N
Revenue Performance and Mix
PFIZER INC · 2026-09-22 · Importance 60 · Surprise 40 · No source text
Acquired and launched products represented 21.2% of Pfizer’s revenue and grew 18% year over year. Pfizer expects a significant decline in COVID-19-related revenue as new medicines, vaccines and oncology products expand, particularly in international markets. The portfolio shift is intended to offset COVID-19 demand declines and patent-cliff pressures.
Key facts
- Acquired and launched products comprise 21.2% of Pfizer's revenues and are growing at +18% year-over-year. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +3.2% | Acquired and launched products comprise 21.2% of Pfizer's revenues and are growing at +18% year-over-year. |